More support for cannabis as an ally in the fight against the coronavirus is possibly coming
Researchers are once again looking into cannabis as a possible treatment for COVID-19. Professor Norbert Kaminski, working in conjunction with Michigan State University (MSU) and GB Sciences, is attempting to treat Cytokine Release Syndrome (CRS), an acute respiratory distress syndrome in COVID-19 patients, utilizing compounds derived from the cannabis plant.
GB Sciences is the Las Vegas-based research and development arm of GBS Global Biopharma, which is based in Canada. The research involves using proprietary cannabinoid-containing complex mixtures (CCCM) in hopes of alleviating conditions that have been traced to macrophage activation syndrome (MAS). Among those who become infected with the SARS-CoV-2 virus, these three conditions, CRS, MAS and ARDS have been isolated as being the leading causes of death.
The CCCMs were developed over time by BGS Global to help diminish the high levels of specific cytokines as well as the pro-inflammatory systems triggered by the virus as a part of your body’s defense system. Professor Kaminski and GB Sciences have a history of collaboration on finding certain mixtures of cannabinoids that have the ability to reduce inflammation caused by HIV and other viruses.
Kaminski, the director of the Institute for Integrative Toxicology, Professor of Pharmacology and Toxicology, as well as being the director of MSU’s center for Research on Ingredient Safety, said in a recent interview, “The human primary blood cell screens preformed at MSU are state-of-the-science models for evaluating the effects of compounds on the human immune system. Our unique human immune cell models allow us to measure the immune modulating properties of these CCCM mixtures on the full complement of immune cell types.”